Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Histologically confirmed carcinoma of unknown primary site~* Progressive disease after treatment with one previous chemotherapy regimen.~* Treatment with one previous immunotherapy or biotherapy regimen.~* No previous treatment with oxaliplatin, capecitabine, or 5-FU.~* Previous treatment with other platinum agents~* Patients must have measurable or evaluable disease~* ECOG Performance Status more than 2~* Adequate bone marrow, liver and kidney function~* Understand the nature of this study and give written informed consent.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* History of treatment of any invasive malignancy within the last 5 years~* Coexistent medical illnesses~* Clinically significant cardiac disease~* Preexisting peripheral neuropathy \> grade 1~* Lack of physical integrity of the upper gastrointestinal tract~* Pre-existing uncontrolled coagulopathy~* Women who are pregnant or lactating~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxaliplatin/Capecitabine (Type: EXPERIMENTAL): All patients received treatment with oxaliplatin 130mg/m2, given intravenously on day 1 of each 21 day cycle. Capecitabine 1000mg/m2 by mouth twice daily was administered on days 1-14 of each cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).